Lucas Kohorst
@lucas
days @dcgco nights @adjacent___
Lucas Kohorst
kohor.st
On the Impossible: Why Cassava Sciences’ simufilam will fail Phase 3 clinical trials and the stock will trade to $2
The text analyzes Cassava Sciences' simufilam, predicting its failure in Phase 3 trials for Alzheimer's disease due to ineffective mechanisms, poor pharmacokinetics, and manipulative data practices.
ontheimpossible.vercel.appWhy I generally don't recommend internal prediction markets or forecasting tournaments to organisations
open.substack.com
Hayden Donnelly
haydendonnelly.netyou can be more informed by reading the news and the charts, than by reading either one alone.
Who Buys Fonts?
gwern.net
Mercury
mercurycomputing.io
Used Commercial and Industrial Equipment | Equipment Seller from Wells Fargo
assetseller.wf.comWells Fargo Equipment Seller Inventory from their Receivable Factoring